ADA preview: novel insulins take diabetes back to the future
This article was originally published in Scrip
Executive Summary
Novel insulins are set to take center stage at the American Diabetes Association meeting this weekend, as last year's data dominance of the SGLT2 antagonists recedes following the march of these products towards the market.